Mirum Pharmaceuticals, Inc.
MIRM
$68.95
-$1.14-1.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 47.17% | 64.09% | 61.20% | 42.93% | 89.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.17% | 64.09% | 61.20% | 42.93% | 89.37% |
| Cost of Revenue | 22.74% | 15.79% | 29.10% | -8.95% | 103.42% |
| Gross Profit | 54.48% | 81.04% | 72.34% | 72.08% | 85.54% |
| SG&A Expenses | 22.48% | 28.61% | 26.44% | 23.05% | 38.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.53% | 30.03% | 32.48% | 21.05% | 41.43% |
| Operating Income | 120.52% | 79.41% | 42.64% | 25.67% | 49.56% |
| Income Before Tax | 119.03% | 77.26% | 44.64% | 31.24% | 40.49% |
| Income Tax Expenses | -175.50% | -36.69% | 64.90% | -356.00% | 39.36% |
| Earnings from Continuing Operations | 120.41% | 76.21% | 41.94% | 33.28% | 39.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 120.41% | 76.21% | 41.94% | 33.28% | 39.65% |
| EBIT | 120.52% | 79.41% | 42.64% | 25.67% | 49.56% |
| EBITDA | 230.71% | 105.81% | 56.11% | 32.94% | 70.52% |
| EPS Basic | 119.27% | 77.40% | 44.27% | 42.60% | 48.09% |
| Normalized Basic EPS | 117.94% | 78.40% | 46.86% | -253.72% | 48.80% |
| EPS Diluted | 116.67% | 77.40% | 44.27% | 42.80% | 47.73% |
| Normalized Diluted EPS | 115.96% | 78.40% | 46.86% | -253.72% | 48.80% |
| Average Basic Shares Outstanding | 5.98% | 5.28% | 4.18% | 16.23% | 16.26% |
| Average Diluted Shares Outstanding | 19.28% | 5.28% | 4.18% | 16.23% | 16.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |